布地奈德联合猪肺磷脂注射液治疗重度新生儿呼吸窘迫综合征的临床疗效分析

Clinical Efficacy Analysis of Budesonide Combined with Porcine Lung Surfactant Injection in the Treatment of Severe Neonatal Respiratory Distress Syndrome

目的 探究重度新生儿呼吸窘迫综合征(NRDS)患儿,在应用猪肺磷脂注射液治疗的基础上,加用布地奈德的价值。方法 选取2022年5月至2023年12月滑县人民医院新生儿重症监护室收入的72例NRDS患儿,依据用药方式差异,将其分为研究组(n=36,实施布地奈德+猪肺磷脂注射液),对照组(n=36,实施猪肺磷脂注射液),比较两组疗效、血气指标[血氧饱和度(SpO_(2))、氧合指数(OI)、动脉血氧分压(PaO_(2))]、炎性因子[超敏C-反应蛋白(hsCRP)、白介素6(IL-6)]、恢复指标(住院时间、机械通气时间、总吸氧时间)与并发症。结果 研究组治疗有效率高于对照组,差异有统计学意义(P<0.05);两组治疗前SpO_(2)、OI、PaO_(2)、hs-CRP、IL-6比较,差异无统计学意义(P>0.05),治疗后研究组SpO_(2)、OI、PaO_(2)水平均高于对照组,hs-CRP、IL-6水平均低于对照组,差异有统计学意义(P<0.05);研究组住院时间、机械通气时间、总吸氧时间均短于对照组,差异有统计学意义(P<0.05)。两组并发症发生率比较差异无统计学意义(P>0.05)。结论 重度NRDS患儿应用猪肺磷脂注射液加用布地奈德能够提高临床疗效,减少炎性反应,且联合用药不会额外增加不良反应,安全性较高,具有临床应用意义。

Objective To explore the value of adding budesonide to the treatment of severe neonatal respiratory distress syndrome(NRDS)with porcine lung surfactant injection.Methods A total of 72 NRDS patients admitted to the Neonatal Intensive Care Unit of Huaxian People’s Hospital from May 2022 to December 2023 were selected.According to the differences in medication methods,they were divided into a study group(n=36,treated with budesonide+porcine lung surfactant injection)and a control group(n=36,treated with porcine lung surfactant injection).The efficacy,blood gas indicators[oxygen saturation(SpO_(2)),oxygenation index(OI),arterial partial pressure of oxygen(PaO_(2))],inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)],recovery indicators(hospital stay,mechanical ventilation time,total oxygen inhalation time),and complications were compared between the two groups.Results The effective treatment rate in the study group was higher than that in the control group,with statistically significant differences(P<0.05).Before treatment,there were no statistically significant differences in SpO_(2),OI,PaO_(2),hs-CRP,and IL-6 between the two groups(P>0.05).After treatment,the levels of SpO_(2),OI,and PaO_(2) in the study group were higher than those in the control group,and the levels of hs-CRP and IL-6 were lower than those in the control group,with statistically significant differences(P<0.05).The hospital stay,mechanical ventilation time,and total oxygen inhalation time in the study group were shorter than those in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of complications between the two groups(P>0.05).Conclusion The application of budesonide combined with porcine lung surfactant injection in severe NRDS patients can improve clinical efficacy,reduce inflammatory responses,and does not increase adverse reactions,making it highly safe and clinically significant.